Results 1 to 10 of about 10,023 (97)

Impact of FCGR2A and FCGR3A Gene Variants on the Response to Rituximab in Patients With Glomerular Diseases. [PDF]

open access: yesPharmacol Res Perspect
ABSTRACT Rituximab is an anti‐CD20 monoclonal antibody used in autoimmune diseases, including glomerular diseases. The FCGR2A (rs1801274) and FCGR3A (rs396991) variants have been suggested to affect rituximab efficacy; this study evaluates their impact on rituximab efficacy in glomerular diseases.
Larrosa-García M   +10 more
europepmc   +2 more sources

Dose–Response Association Between Systemic and Dermatologic Glucocorticoid Use and Type 2 Diabetes Mellitus: A Nationwide Case–Control Study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To investigate the association and dose–response between systemic and topical glucocorticoids and odds of Type 2 diabetes mellitus. Materials and Methods We conducted a nationwide case–control study using Danish registry data from 2013 to 2021. People aged 40 years or older with incident type 2 diabetes mellitus (n = 149 113) were matched
David Vadsholt   +6 more
wiley   +1 more source

Platelet Levels Associated With Bleeding Risk for Dental Interventions: A Systematic Review

open access: yesOral Diseases, EarlyView.
ABSTRACT Objectives To evaluate evidence in relation to postoperative bleeding in humans aged ≥ 16 with preoperative platelet counts < 50,000/μL, compared to those above, undergoing dental interventions. Methods Quantitative synthesis without meta‐analysis was conducted through an electronic search conducted on Ovid MEDLINE and Embase from 1946 to ...
Guang Xu David Lim   +3 more
wiley   +1 more source

CD4+ T Cells Predict Relapse in Pemphigus Vulgaris Treated With Rituximab: A Retrospective Study

open access: yesOral Diseases, EarlyView.
ABSTRACT Objective This study evaluated the CD4+ T‐cell role in mediating post‐Rituximab Pemphigus vulgaris (PV) relapse, comparing CD4+ count and CD4+/CD20+ ratio between patients who achieved remission and those who relapsed. Methods The clinical course of 27 PV patients treated with Rituximab was evaluated after a 32‐month median follow‐up. CD4+ and
Simone Liguori   +9 more
wiley   +1 more source

Association of Childhood Acute Leukemia With Autoimmune Diseases

open access: yesInternational Journal of Cancer, Volume 159, Issue 5, Page 1188-1195, 1 September 2026.
A possible link exists between various pediatric autoimmune diseases (AIDs) and increased risk of childhood leukemia. Although immune dysregulation is a key feature of these conditions, the connection between them remains unclear. In this study, using cancer registry data in Finland, the authors examined associations between AIDs and childhood acute ...
Ida Pellikka   +4 more
wiley   +1 more source

Thrombotic Antiphospholipid Syndrome: A Long Term Follow‐up of Patients With Recurrent Pregnancy Loss and Antiphospholipid Antibodies From the APS 1994 Study

open access: yesAmerican Journal of Reproductive Immunology, Volume 96, Issue 1, July 2026.
ABSTRACT Problem There is a paucity of studies on the incidence and predictors of thrombotic antiphospholipid syndrome (APS) after pregnancy in patients with recurrent pregnancy loss (RPL) and antiphospholipid antibodies (aPL). This prospective study aimed to assess the long‐term prognosis, including the occurrence of thrombosis and associated risk ...
Minami Ashio   +8 more
wiley   +1 more source

Platelet Transfusion Is Associated With Increased Thrombosis and In‐Hospital Mortality Among Patients Hospitalized With Platelet Consumptive Disorders

open access: yesEuropean Journal of Haematology, Volume 117, Issue 1, Page 245-257, July 2026.
ABSTRACT Background Platelet transfusion is commonly used to reduce bleeding risk in platelet consumptive disorders. However, platelets may also promote thromboinflammatory pathways, and contemporary data evaluating the association between platelet transfusion, thrombosis, and mortality in this population are limited.
Manas Pustake   +6 more
wiley   +1 more source

Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease

open access: yesInternal Medicine Journal, Volume 56, Issue 7, Page 1218-1239, July 2026.
Abstract Idiopathic multicentric Castleman disease (iMCD) is a rare condition. The pathogenesis is incompletely understood; however, interleukin‐6 (IL‐6) is a major mediator. The clinical presentation is heterogeneous, from mild constitutional symptoms to severe multi‐organ failure.
Dipti Talaulikar   +16 more
wiley   +1 more source

Disease Remission: A Scoping Review With Thematic Analysis of the Scientific Literature With Implications for Chronic Rhinosinusitis

open access: yesInternational Forum of Allergy &Rhinology, Volume 16, Issue 6, Page 615-629, June 2026.
ABSTRACT Background Remission, a term used to describe a goal of treatment for some chronic diseases, has recently been proposed for chronic rhinosinusitis (CRS). However, it is unclear what remission means for CRS and why it should serve as a goal in the present‐day treatment of CRS.
Nikhil Parail   +7 more
wiley   +1 more source

Single‐Cell RNA Sequencing Informs Precision Targeting of Monogenic Lupus Associated With IKZF1 Haploinsufficiency

open access: yesArthritis &Rheumatology, Volume 78, Issue 6, Page 1231-1244, June 2026.
Objective This study aimed to investigate the mechanisms of immune dysregulation in a pediatric patient with monogenic lupus driven by IKZF1 haploinsufficiency. Methods Peripheral immune cells from a patient with IKZF1 haploinsufficiency, patients with lupus with no currently known genetic mutations, and healthy controls were analyzed using single‐cell
Qi Zheng   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy